Business UpdateJun 18, 2026, 01:26 PM
Pfizer Reaffirms FY2026 Guidance: Revenue $59.5-62.5B, EPS $2.80-3.00
AI Summary
Following its Chief Financial Officer transition announcement, Pfizer Inc. reaffirmed its fiscal year 2026 financial guidance. The company expects revenues in the range of $59.5 billion to $62.5 billion and Adjusted Diluted EPS in the range of $2.80 to $3.00. This guidance was initially introduced in December 2025 and previously reaffirmed in May 2026.
Key Highlights
- Pfizer reaffirmed its fiscal year 2026 revenue guidance of $59.5 billion to $62.5 billion.
- The company reaffirmed its fiscal year 2026 Adjusted Diluted EPS guidance of $2.80 to $3.00.
- This guidance was initially introduced on December 16, 2025.
- The guidance was previously reaffirmed during the first quarter earnings call on May 5, 2026.
- The reaffirmation follows the disclosure of a Chief Financial Officer transition announcement on June 18, 2026.
Price Impact
More from PFE